Indefinite Delivery Contract 75N91024D00004
Award Date
1/25/24
Last Date to Order
1/24/29
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The University of Texas MD Anderson Cancer Center was awarded an indefinite delivery, indefinite quantity (IDIQ) contract from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to support the PREVENT Preclinical Drug Development Program. This multiple award IDIQ has a $74,995,000 ceiling and a 5-year base period with a 5-year option. It covers three pools of services: preclinical efficacy and biomarker evaluation, preclinical GMP product development and...
This federal Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to the University of Texas MD Anderson Cancer Center, a major academic medical center and NCI-designated comprehensive cancer center. The $59,250 multiple-award IDC, issued under the NCI Cancer Genome Atlas Program Tissue Purchase master IDIQ, facilitates the acquisition of tumor and adjacent normal tissue specimens to support the Cancer...
The Indefinite Delivery Contract (IDC) with ID 75N91024D00006 was awarded by the National Cancer Institute (NCI), a civilian agency, to the Weill Medical College of Cornell University. This multiple-award IDC, with a ceiling value of $149,995,000, supports the PREVENT Cancer Preclinical Drug Development Program through the provision of preclinical research services. The IDC's scope includes evaluating the efficacy of potential cancer preventive agents, identifying relevant biomarkers, developing...
This is a multiple award Indefinite Delivery Contract (IDC) issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services. The contract has a ceiling value of $9,950,000 and was awarded to the University of Oklahoma (OU) to provide preclinical research and development services related to cancer prevention and treatment. The task orders issued under this IDC cover a range of preclinical oncology research activities, including the evaluation of...
The National Cancer Institute (NCI) awarded a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value to The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year IDC contract includes three technical pools: Preclinical Efficacy and Biomarkers, Preclinical Services for Product...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health within the Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $74,995,000 multiple-award contract, titled the "PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers," supports preclinical efficacy and biomarker evaluation, manufacturing, and...
This Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health, to the University of Texas MD Anderson Cancer Center, a part of the University of Texas System. The $317,760 single-award IDC supports the NCI Cancer Genome Atlas Program Tissue Purchase, an initiative to collect cancer tissue samples and associated data to advance the Cancer Genome Atlas (TCGA) research program. Under this IDC, the University of Texas...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson). The contract supports the collection of tissue samples and data from various cancer types for the Cancer Genome Atlas (TCGA) program, which aims to comprehensively characterize the genomic changes associated with different cancer types. As a leading cancer research institution, MD Anderson...
This indefinite delivery contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the University of Alabama at Birmingham (UAB) to support the agency's Preclinical Prevent Cancer Program. The program focuses on evaluating the preclinical efficacy and identifying intermediate biomarkers for potential cancer prevention agents prior to clinical trials. Under this $29.8 million multiple-award IDC, UAB has been issued multiple...
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), a civilian agency under the Department of Health and Human Services, to the University of Oklahoma (OU) to support the PREVENT Cancer Preclinical Drug Development Program. The $149,995,000 IDIQ contract covers the continued evaluation of the efficacy and pharmacodynamic/efficacy biomarkers of potential cancer preventive agents, as well as preclinical product development, manufacturing, and...